ADCY4 Cancer Research Results

ADCY4, adenylate cyclase 4; adenylyl cyclase 4; AC4: Click to Expand ⟱
Source:
Type:

ADCY4 (adenylate cyclase 4; adenylyl cyclase 4; AC4) is a membrane-associated enzyme that converts ATP into cyclic AMP (cAMP) in response to G-protein-coupled-receptor signalling. Through cAMP, ADCY4 can influence PKA, CREB, EPAC, calcium regulation, transcription, metabolism, proliferation and differentiation. Altered ADCY4 expression or DNA methylation has been identified in some cancers, including breast cancer, suggesting potential use as a biomarker and signalling regulator. However, current evidence does not establish ADCY4 as a broadly oncogenic or tumour-suppressive target across cancers.



Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
7105- GEN,    Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer
- Trial, Pca, NA
Risk↓, Myc↓, PTEN↑, Dose↝, NOTCH3↑, JAG1↑, ADCY4↑, NEU1↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ADCY4↑, 1,   JAG1↑, 1,   NEU1↑, 1,  

Cell Death(tgid=5) ⓘ

Myc↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

NOTCH3↑, 1,   PTEN↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ADCY4, adenylate cyclase 4; adenylyl cyclase 4; AC4
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1580  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page